- Home
- ANTX vs MOLN Comparison
ANTX vs MOLN Comparison
Compare ANTX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTX | MOLN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 170.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANTX | MOLN |
|---|---|---|
| Price | $4.93 | $3.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 194.6K | 1.5K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $3.53 |
| 52 Week High | $7.19 | $5.36 |
Technical Indicators
Market Signals| Indicator | ANTX | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 40.93 |
| Support Level | $3.91 | N/A |
| Resistance Level | $5.15 | $4.39 |
| Average True Range (ATR) | 0.34 | 0.12 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 21.49 | 0.00 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.